Nexus

Immuno-Oncology in vitro assays

Therapeutic Area

As a pre-clinical Immunology CRO, we provide services to test novel immuno-oncology therapeutics that use the immune system to prevent, control or destroy tumours.

Recent therapeutic advances in IO include the use of check-point-inhibitors, bispecific antibodies and cellular therapeutics within the clinic. Our assays are designed to test single and combinatorial therapy using all therapeutic modalities. Our T cell assays cover key mechanisms such as CD8 cytotoxicity, NK assays cover ADCC and MHC independent cytotoxicity.

Frequently Asked Questions

Do you offer 3D tumour models to study immune cell mediated tumour killing?

Yes, we provide 2D and 3D in vitro tumor models to study direct or immune-mediated tumor killing for immuno-oncology research. Our 2D and 3D models are used to test efficacy of  mono and combination therapeutics.

What tumour types can you work with in your assays? 

We work with a wide range of tumor types, including lung, breast, colorectal, and melanoma. Our immune-mediated tumor killing assays use real-time imaging and key inflammatory cytokines such as IFNγ to assess therapeutic effects. We have a panel of clinically relevant NucLight Red labelled tumour cell lines for screening and can include new tumour types, on request.  

What type of therapeutics can be tested  in your assays? 

Our in vitro immune oncology assays are designed to test therapeutics that target both immune cells and tumour cells including small molecules, monoclonal antibodies, checkpoint inhibitors, cellular therapies and antibody-drug conjugates.

What Our Partners say about Nexus

The team at Nexus are fantastic! Great adaptability at working with highly bespoke requests and difficult experiments to keep the project on track and deliver within aggressive timelines. A highly flexible, friendly and efficient team to work with!

Wayne Paes

Principal Scientist. Greywolf Therapeutics

We have been delighted with our interactions with  Nexus BioQuest. I first reached out to them after a recommendation from a former colleague. I appreciated their ability to suggest immunoassay options to address the question of interest (as a neurobiologist, the immune system definitely works in mysterious ways!). This was further bolstered by exemplary attention to detail when putting together a  work package proposal which was then efficiently executed. The skill set, responsiveness, knowledge base, effort, effectiveness, transparent and regular communication were all outstanding and I have no hesitation whatsoever in recommending Nexus BioQuest as a partner of choice.

Caroline Benn

Chief Scientific Officer and co-founder

Our work with Nexus BioQuest initially started with developing a novel T cell assay and grew from there into a much larger screening project. Working with Nexus has been a fantastic experience, marked by their deep expertise in immunology and friendly staff. At the onset of the project, Nexus really took the time to understanding of our project needs, setting us up for success throughout. Nexus distinguishes themselves by their enthusiasm, knowledge, and commitment to excellence, with contributed significantly to the development of a tailored assay that exceeded our  expectations.

Ryan Shaler

Director, Sonata Therapeutics

I would like to thank the team at Nexus BioQuest for providing an excellent and professional service supporting our R&D development activities. The Nexus team were great to work with from contract signature to delivery of final reporting. I would certainly recommend their contract services to companies seeking immunology expertise and agile research solutions.

Andrew Mearns Spragg

Chief Scientific Officer, Jellagen

Our experience of working with Nexus was excellent, we felt they held the expertise required for the task at hand, working well together as a high performing  team and presenting well researched solutions to assay development and the problems encountered. We wanted a fresh outlook for assay development for our  project and the team were able to rapidly research the literature and come up with proposals. The team were flexible and dynamic in their approach providing  honest feedback and critique to methods and results.  We would certainly work with Nexus again and would not hesitate to  recommend them as a CRO for immunological assay development.

Seema Patel

Immuno-oncology Alliance Science Program Lead, LifeArc

Working with Nexus BioQuest has been an absolutely wonderful experience. As a smaller biotechnology company that relies heavily on CRO support to execute our lab-based activities, we could not have found a better biological team to partner with. We needed a team to generate our biological package for a new pipeline candidate and we were fortunate to find Nexus and have them deliver a wonderful data package that will help the Bluejay team move our program forward. Working with this group felt like having an internal Bluejay R&D team from ease of execution, to great scientific discussions and troubleshooting, and having the feeling that the Nexus team was truly invested in the success of our program. I cannot recommend the Nexus team enough and will greatly look forward to collaborating with them again on our next programs and projects!

Hilario Ramos

Sr. Director, Head of Immunology

Drug Discovery Tool

Find the right immune assay for your therapeutic area, modality and target using our interactive Drug Discovery Tool.

Explore now
Speak to a Scientist

Learn how the Nexus BioQuest team can help with your pre-clinical drug discovery programs.

Schedule a call